75.5
[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 11 Jan;76(1):4-1.
[]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 1 Sep;5():15-6.
[]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. Jun; Suppl :S1-7.
[4]. M B Slabaugh, et al. Hydroxyurea-resistant vaccinia virus: overproduction of ribonucleotide reductase. J Virol. 186 Nov;6():56-14.
[5]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 5 Dec;(1):1486-.
H4-H61
P8-P45-P51
GHS8
77